Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4915437 | 0.85 | ALDH1A1 (0.43) | ALDH1A1KDM4EFPR2KMT2AMAPT | |
| SCHEMBL8266745 | 0.82 | ALDH1A1 (0.58) | GAAALDH1A1KDM4EKMT2AMAPT | |
| SCHEMBL28509631 | 0.80 | GAA (0.40) | GAAALDH1A1KDM4EKMT2AMAPT | |
| SCHEMBL9589872 | 0.80 | ALDH1A1 (0.58) | ALDH1A1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL12391316 | 0.80 | ALDH1A1 (0.42) | ALDH1A1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL31373551 | 0.78 | ALDH1A1 (0.41) | ALDH1A1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL14164203 | 0.77 | NR1H2 (0.47) | ALDH1A1KDM4ENR1H2KMT2AMAPT | |
| SCHEMBL11357348 | 0.76 | NR4A2 (0.47) | GAAALDH1A1KDM4EKMT2AMAPT | |
| SCHEMBL10911266 | 0.76 | MAPT (0.40) | ALDH1A1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL15030294 | 0.75 | KDM4E (0.42) | ALDH1A1KDM4EFPR2KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112279848-A | Pan-JAKs inhibitor and application thereof | 四川海思科制药有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-20080227774-A1 | 5,5-DISUBSTITUTED-INDOLIZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-18 | — | — | US | disclosed |
| EP-1910337-A2 | HETEROARYL DERIVATIVES FOR TREATING VIRUSES | GENELABS TECHNOLOGIES, INC. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2006138744-A2 | HETEROARYL DERIVATIVES FOR TREATING VIRUSES | GENELABS TECHNOLOGIES, INC. (US) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227774-A1 | 5,5-DISUBSTITUTED-INDOLIZINONE COMPOUNDS | CYP3A5, IPO5, IDO1 | GAA 2494/4885ALDH1A1 372/4885KDM4E 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.